DE69817393D1 - Neue heterozyklische verbindungen - Google Patents

Neue heterozyklische verbindungen

Info

Publication number
DE69817393D1
DE69817393D1 DE69817393T DE69817393T DE69817393D1 DE 69817393 D1 DE69817393 D1 DE 69817393D1 DE 69817393 T DE69817393 T DE 69817393T DE 69817393 T DE69817393 T DE 69817393T DE 69817393 D1 DE69817393 D1 DE 69817393D1
Authority
DE
Germany
Prior art keywords
substituted
group
atom
heterocyclic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69817393T
Other languages
English (en)
Other versions
DE69817393T2 (de
Inventor
Ayumu Kurimoto
Tetsuhiro Ogino
Hajime Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of DE69817393D1 publication Critical patent/DE69817393D1/de
Application granted granted Critical
Publication of DE69817393T2 publication Critical patent/DE69817393T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
DE69817393T 1997-11-28 1998-11-26 Neue heterozyklische verbindungen Expired - Lifetime DE69817393T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP34742297 1997-11-28
JP34742297 1997-11-28
JP36745197 1997-12-11
JP36745197 1997-12-11
JP36744997 1997-12-17
JP36744997 1997-12-17
PCT/JP1998/005318 WO1999028321A1 (en) 1997-11-28 1998-11-26 Novel heterocyclic compounds

Publications (2)

Publication Number Publication Date
DE69817393D1 true DE69817393D1 (de) 2003-09-25
DE69817393T2 DE69817393T2 (de) 2004-06-17

Family

ID=27341247

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69817393T Expired - Lifetime DE69817393T2 (de) 1997-11-28 1998-11-26 Neue heterozyklische verbindungen

Country Status (12)

Country Link
US (1) US6329381B1 (de)
EP (1) EP1035123B1 (de)
JP (1) JP4375901B2 (de)
KR (1) KR100613634B1 (de)
AT (1) ATE247654T1 (de)
AU (1) AU732361B2 (de)
CA (1) CA2311742C (de)
DE (1) DE69817393T2 (de)
ES (1) ES2205573T3 (de)
NZ (1) NZ504800A (de)
TW (1) TWI222973B (de)
WO (1) WO1999028321A1 (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
US20030133913A1 (en) * 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
DE60230340D1 (de) * 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
DE60218525T2 (de) * 2001-12-18 2007-11-22 CV Therapeutics, Inc., Palo Alto A2a adenosinrezeptorantagonisten
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
NZ534566A (en) * 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7754728B2 (en) * 2002-09-27 2010-07-13 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound and use thereof
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖ誘発性の表皮の新形成の予防的治療
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
CA2521682A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
CA2534042A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Compositions for encapsulation and controlled release
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
AR045261A1 (es) 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
AU2004268616B2 (en) 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
JP5128815B2 (ja) 2003-08-27 2013-01-23 スリーエム イノベイティブ プロパティズ カンパニー アリールオキシ置換およびアリールアルキレンオキシ置換イミダゾキノリン
CN1845736A (zh) * 2003-09-02 2006-10-11 3M创新有限公司 治疗粘膜相关病症的方法
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
SG149828A1 (en) 2003-10-03 2009-02-27 3M Innovative Properties Co Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050222198A1 (en) * 2003-12-22 2005-10-06 K.U. Leuven Research & Development, Gerhard Puerstinger And Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1728792A4 (de) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-oxoadeninverbindung
NZ549903A (en) 2004-03-26 2010-04-30 Astrazeneca Ab 9-substituted 8-oxoadenine compound
JP2007531729A (ja) * 2004-04-02 2007-11-08 アデノシン、セラピューティックス、リミテッド、ライアビリティ、カンパニー Ａ２ａアデノシンレセプターの選択的アンタゴニスト
EP1735010A4 (de) * 2004-04-09 2008-08-27 3M Innovative Properties Co Verfahren, zusammensetzung und formulierungen für die verabreichung von immunantwortmodifikatoren
DK1765310T3 (en) 2004-05-28 2016-01-11 Oryxe MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006023381A1 (en) * 2004-08-16 2006-03-02 Taigen Biotechnology Pyrimidinone compounds
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
PT1824482E (pt) 2004-12-17 2014-05-13 Anadys Pharmaceuticals Inc Compostos 3h-oxazolo e 3h-tiazolo[4,5-d]pirimidin-2-ona 3,5- -di-substituídos e 3,5,7-tri-substituídos e seus pró- -fármacos
US20060252791A1 (en) * 2004-12-21 2006-11-09 Gilead Sciences, Inc. Imidazo[4,5-c]pyridine compound and method of antiviral treatment
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
HUE025749T2 (en) 2004-12-30 2016-04-28 Meda Ab Use of Imiquimod to treat skin metastases from breast cancer
EP1844201B1 (de) 2005-02-04 2016-08-24 3M Innovative Properties Company Wässrige gelformulierungen mit immunreaktionsmodifikatoren
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
WO2006107851A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008540396A (ja) 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびｃ型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての２−アミド−６−アミノ−８−オキソプリン誘導体
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
EP1939202A4 (de) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Neue adeninverbindung
US20090192153A1 (en) * 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
JPWO2007060918A1 (ja) 2005-11-24 2009-05-07 大日本住友製薬株式会社 新規なメモリーｃｔｌ誘導増強剤
US8951528B2 (en) * 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
JP5345527B2 (ja) * 2006-06-22 2013-11-20 アナディス ファーマシューティカルズ インク プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TWI360549B (en) * 2006-07-07 2012-03-21 Gilead Sciences Inc Novel pyridazine compound and use thereof
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
EP2040712B1 (de) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonat- und carbamat-prodrugs von thiazolo [4,5-d]-pyrimidinen
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
AU2008227128B2 (en) 2007-02-07 2012-12-06 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
US8063051B2 (en) * 2007-03-19 2011-11-22 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
EP2138497A4 (de) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Neue adeninverbindung
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
EP2170888B1 (de) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purinderivate und ihre verwendung als modulatoren des toll-like-rezeptors 7
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
WO2009091031A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
BRPI0907907A2 (pt) * 2008-02-07 2015-07-28 Univ California Método para inibir ou trata câncer de bexiga superficial em um mamífero, e, uso de um agonista de tlr 7
BRPI0923305B1 (pt) * 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2607365A1 (de) 2009-02-11 2013-06-26 The Regents of The University of California Modulatoren des toll-ähnlichen Rezeptors und Behandlung von Krankheiten
TWI394757B (zh) 2009-04-28 2013-05-01 Zenyaku Kogyo Kk 嘌呤衍生物及使用它之抗腫瘤劑
CN102482233A (zh) 2009-05-21 2012-05-30 阿斯利康(瑞典)有限公司 新颖的嘧啶衍生物和它们在治疗癌症和其它疾病中的用途
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EA201500447A1 (ru) * 2009-05-27 2017-03-31 Селекта Байосайенсиз, Инк. НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
MX343908B (es) 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
KR101793300B1 (ko) 2009-10-22 2017-11-02 길리애드 사이언시즈, 인코포레이티드 특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체
EP2507237A1 (de) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Über toll-like-rezeptoren (tlr) agierende imidazochinoline
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
NZ603155A (en) 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
WO2011150264A2 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
IT1401281B1 (it) * 2010-08-05 2013-07-18 Univ Firenze Preparazione di coniugati fra derivati dell'adenina e proteine allergeniche e loro uso in immunoterapia specifica per il trattamento delle malattie allergiche.
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
EP2651937B8 (de) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Imidazo-[4, 5 -c]-chinolin-1-yl-derivat für die therapie
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
AR085633A1 (es) * 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
SI3590928T1 (sl) 2011-04-08 2021-10-29 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za zdravljenje virusnih okužb
LT2709989T (lt) 2011-05-18 2018-04-10 Janssen Sciences Ireland Uc Chinazolino dariniai, skirti virusinių infekcijų ir kitų ligų gydymui
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
WO2012167081A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CA2843274A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
BR112014011162A2 (pt) 2011-11-09 2017-05-09 Janssen R&D Ireland derivados purínicos para o tratamento de infecções virais
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
DK2850067T3 (da) 2012-05-18 2017-11-06 Sumitomo Dainippon Pharma Co Ltd Carboxylsyreforbindelser
WO2014009509A1 (en) 2012-07-13 2014-01-16 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
BR112015002524B1 (pt) 2012-08-10 2021-11-03 Janssen Sciences Ireland Uc Derivados de alquilpirimidina, composição farmacêutica que os compreende e uso dos mesmos
EP2712866A1 (de) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-Triazinderivate zur Behandlung von Virusinfektionen
PT2906563T (pt) 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
NZ748345A (en) 2012-11-16 2020-04-24 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
ES2828735T3 (es) 2013-01-07 2021-05-27 Univ Pennsylvania Composiciones y métodos para el tratamiento del linfoma cutáneo de células T
EA035174B1 (ru) 2013-02-21 2020-05-12 Янссен Сайенсиз Айрлэнд Юси Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8
US10485861B2 (en) 2013-03-14 2019-11-26 President And Fellows Of Harvard College Nanoparticle-based compositions
ES2625456T3 (es) * 2013-03-29 2017-07-19 Janssen Sciences Ireland Uc Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas
AU2014270418B2 (en) 2013-05-24 2017-11-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
KR102311234B1 (ko) 2013-06-27 2021-10-12 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 기타 질환의 치료를 위한 피롤로[3,2-d]피리미딘 유도체
SG11201510736PA (en) 2013-07-30 2016-02-26 Janssen Sciences Ireland Uc THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
EP3556353A3 (de) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme
EA201692512A1 (ru) 2014-06-25 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
UA117634C2 (uk) 2014-08-15 2018-08-27 Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. Піролопіримідинові сполуки, що використовуються як агоніст tlr7
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
CA2969587A1 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
US20180110784A1 (en) * 2015-04-09 2018-04-26 The Regents Of The University Of California Synthetic tlr4 and tlr7 ligands to prevent, inhibit or treat liver disease
KR20180053318A (ko) 2015-09-17 2018-05-21 제이알엑스 바이오테크놀로지, 인코포레이티드 피부 수화 또는 보습을 향상시키기 위한 접근법
CN108348618B (zh) 2015-09-29 2021-06-15 大日本住友制药株式会社 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
TWI558709B (zh) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
JP7171444B2 (ja) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染治療用のジヒドロピラノピリミジン
AU2017320742B2 (en) * 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
SG10202010317VA (en) 2016-09-29 2020-11-27 Janssen Sciences Ireland Unlimited Co Pyrimidine prodrugs for the treatment of viral infections and further diseases
ES2906439T3 (es) 2016-12-05 2022-04-18 Apros Therapeutics Inc Compuestos de pirimidina que contienen grupos ácidos
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
EP3603619B1 (de) 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Impfstoff-adjuvans-formulierung
US10494370B2 (en) * 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
CN111757755A (zh) 2017-12-21 2020-10-09 大日本住友制药株式会社 包含tlr7激动剂的组合药物
CA3034912A1 (en) 2018-02-28 2019-08-28 Pfizer Inc. Il-15 variants and uses thereof
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
US12365714B2 (en) 2018-03-05 2025-07-22 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
PE20210127A1 (es) 2018-05-23 2021-01-19 Pfizer Anticuerpos especificos para cd3 y sus usos
TWI803637B (zh) 2018-05-23 2023-06-01 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
US10857153B2 (en) 2018-06-04 2020-12-08 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
WO2020022272A1 (ja) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 インフルエンザワクチンを含む組成物
US20210213010A1 (en) * 2018-07-24 2021-07-15 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
BR112022009723A2 (pt) 2019-12-17 2022-08-09 Pfizer Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8511222D0 (en) 1985-05-02 1985-06-12 Wellcome Found Antiviral compounds
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
NZ329798A (en) 1996-07-03 1999-04-29 Japan Energy Corp Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same
IL129319A0 (en) 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases

Also Published As

Publication number Publication date
ATE247654T1 (de) 2003-09-15
KR20010032571A (ko) 2001-04-25
AU1260299A (en) 1999-06-16
CA2311742C (en) 2009-06-16
NZ504800A (en) 2001-10-26
CA2311742A1 (en) 1999-06-10
EP1035123A1 (de) 2000-09-13
US6329381B1 (en) 2001-12-11
WO1999028321A9 (en) 1999-09-10
TWI222973B (en) 2004-11-01
EP1035123B1 (de) 2003-08-20
WO1999028321A1 (en) 1999-06-10
KR100613634B1 (ko) 2006-08-18
ES2205573T3 (es) 2004-05-01
DE69817393T2 (de) 2004-06-17
EP1035123A4 (de) 2001-12-12
JP4375901B2 (ja) 2009-12-02
AU732361B2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
DE69817393D1 (de) Neue heterozyklische verbindungen
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
DK459086A (da) Quinazolinderivater
ATE145906T1 (de) Benzamid-derivate
DK132188A (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
DK0420121T3 (da) Antitumormiddel
DE69001722D1 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
DK0420224T3 (da) Anthihepatopatisk middel
FI895139A0 (fi) Pyrrolidinderivat.
DE3762342D1 (de) 1-acylaminomethylimidazo(1,2-a) chinolinderivate, ihre herstellung und therapeutische verwendung.
DE69523819D1 (de) Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
DE3884878D1 (de) Uricosuretische Zusammensetzung.
DE3782235D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
DE69501810D1 (de) Verwendung von 5-Thia-1,4-Diazabicyclo [4.2.0] Octane-3,8-dioxo Verbindungen in der Antitumor-Therapie

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., OSAKA, JP